![](https://www.diabetesnews.com/wp-content/uploads/2014/02/FDA-Logo-150x150.jpg)
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.